BIO 1000 cancer research assessment: a planning guide

Read the constraint before you read anything else, because it disqualifies the cancers most people would pick. The assessment specifies a cancer of the digestive system or the endocrine system. Breast, lung, prostate, skin and blood cancers are all outside that boundary, and a paper about one of them fails the first question no matter how well it is written. Inside the boundary, though, you have plenty of scope and no shortage of well-documented options: the digestive system includes the oesophagus, stomach, small and large intestine, and the accessory organs, which the brief explicitly permits, meaning the liver, gallbladder and pancreas. The endocrine system gives you thyroid, parathyroid, adrenal, pituitary and the pancreatic islet cells. Decide early, because every subsequent question is answered about that one cancer, and switching halfway through costs you the whole draft rather than one section of it.

There is a strategic reason to choose an endocrine cancer, and it is worth taking seriously. Question four asks which aspects of homeostasis the spreading disease affects and which self-regulating systems are upset. For most cancers the honest answer is diffuse: the tumour consumes resources, provokes inflammation, and eventually disrupts whatever organ it invades. For an endocrine cancer the answer is precise, because the affected organ is itself a regulator. A thyroid tumour disturbs a named negative feedback loop running between the hypothalamus, the pituitary and the thyroid, with measurable hormone levels at each step. A pancreatic islet cell tumour disturbs glucose regulation directly. Choosing one of those turns the hardest question in the assessment into the easiest one, and it lets you answer in the language of feedback loops that a general biology course is teaching.

Question two asks for biological changes at two levels and most papers deliver one. At the level of the cell, you are describing what a mutation does to the control of division: loss of the brakes that stop a damaged cell dividing, loss of the signal that tells a damaged cell to die, and acquisition of the ability to keep dividing indefinitely. At the level of the major organ, you are describing what happens to the organ's structure and function as a growing mass displaces normal tissue, obstructs a duct or lumen, recruits its own blood supply, and eventually breaches its boundary. Write them as two separate passages with two separate headings. The question asks about progression as well, so the organ-level answer should have a sequence to it rather than a state: what the organ looks like early, what changes as the mass grows, and what changes again once the tumour leaves the organ it started in.

Question three, the characteristics distinguishing cancer cells from normal ones, has a well-known framework behind it and using it will lift the paper. The hallmarks of cancer, set out by Hanahan and Weinberg and extended in 2022, describe the capabilities a cell must acquire to become malignant: sustaining its own growth signalling, evading growth suppressors, resisting cell death, achieving replicative immortality, inducing blood vessel growth, and activating invasion and metastasis, alongside enabling characteristics such as genome instability. Do not simply list them. Pick the four or five that are most relevant to your chosen cancer and say how each one shows up in it, because that is the difference between reciting a framework and applying it. If your cancer is one where a particular hallmark is unusually prominent, say so and explain why, since that is the observation a marker will remember.

Questions five and six ask about therapies and lifestyle, and both carry an explicit mechanism requirement. How do these therapies work biologically is not answered by naming chemotherapy and radiation. Say what the mechanism is: a cytotoxic agent damages dividing cells and therefore hits rapidly dividing tissue hardest, which is also why it produces the side effects it does; a targeted therapy blocks a specific receptor or enzyme the tumour depends on; surgery removes the mass but not disseminated cells. The lifestyle question then has an unusual second half asking how you incorporate these choices into your own daily life, which means it wants a personal answer alongside the biology. Answer both parts, briefly and honestly. The evidence on lifestyle and cancer risk is stronger for some factors than others, so distinguish a modifiable risk factor with good evidence behind it from a general recommendation to eat well, which applies to everyone and says nothing about this disease.

The last question is comparative and it is where a good paper closes strongly. How are the biological changes of this cancer, at the cell and organ level, similar to and different from other cancers. The similarity is the hallmarks framework: the acquired capabilities are broadly shared, which is why the framework exists at all. The difference is tissue of origin and what that tissue does, which determines the symptoms, the pattern of spread, and whether the organ's loss of function matters as much as the mass itself. That last point is the strongest thing you can say if you chose an endocrine cancer, because there the loss of regulatory function can harm the patient before the tumour's size ever does. Format in APA sixth edition, as the brief specifies, which is an older edition than most courses now use, so check your citation generator's setting rather than assuming its default is right.